<DOC>
	<DOCNO>NCT02195895</DOCNO>
	<brief_summary>The purpose study determine year alendronate treatment maintain increase bone mass density ( BMD ) compare baseline BMD value people chronic SCI . This study also investigate 1 ) alendronate therapy increase bone strength people chronic SCI , 2 ) safety alendronate , 3 ) effect alendronate serum marker bone metabolism .</brief_summary>
	<brief_title>Effect Alendronate Bone People With Chronic Spinal Cord Injury Previously Treated With Teriparatide</brief_title>
	<detailed_description>This extension study enroll individual complete treatment parent protocol `` Effect Teriparatide , Vibration Combination Bone Mass Bone Architecture Chronic Spinal Cord Injury '' teriparatide extension protocol . This study allow individual previously receive teriparatide treat year alendronate maintain bone may gain possibly increase bone mass . Termination teriparatide follow bone loss anti-resorptive therapy initiate , approach optimal continue treatment current group participant .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Prior enrollment protocol `` Effect Teriparatide , Vibration Combination Bone Mass Bone Architecture Chronic Spinal Cord Injury '' , ( NCT ID # NCT01225055 ) . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Ability understand willingness sign write informed consent . Individual renal insufficiency ( calculated creatinine clearance &lt; 30 ml/min ) . Individuals able sit stand upright least 30 minute take medication . Individuals poor dental hygiene . Individuals esophageal abnormality . Individuals able tolerate alendronate treatment . Individuals able return study visit . Patients may receive investigational agent . Other medical condition opinion investigator would preclude subject completing study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Teriparatide</keyword>
	<keyword>Alendronate</keyword>
	<keyword>Alendronic Acid</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Fracture</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Metabolic Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Spinal Cord Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Nervous System</keyword>
	<keyword>Wounds Injuries</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>